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trafficking
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Abstract
Background: Pro-inflammatory cytokines accumulate in the brain with age and Alzheimer’s disease and can impair
neuron health and cognitive function. Brain-derived neurotrophic factor (BDNF) is a key neurotrophin that supports
neuron health, function, and synaptic plasticity. The pro-inflammatory cytokine interleukin-1β (IL-1β) impairs BDNF
signaling but whether it affects BDNF signaling endosome trafficking has not been studied.
Methods: This study uses an in vitro approach in primary hippocampal neurons to evaluate the effect of IL-1β on
BDNF signaling endosome trafficking. Neurons were cultured in microfluidic chambers that separate the environments
of the cell body and its axon terminal, enabling us to specifically treat in axon compartments and trace vesicle trafficking
in real-time.
Results: We found that IL-1β attenuates BDNF signaling endosomes throughout networks in cultures. In IL-1β-treated
cells, overall BDNF endosomal density was decreased, and the colocalization of BDNF endosomes with presynaptic
terminals was found to be more than two times higher than in control cultures. Selective IL-1β treatment to the
presynaptic compartment in microfluidic chamber attenuated BDNF endosome flux, as measured by reduced BDNF-GFP
endosome counts in the somal compartment. Further, IL-1β decreased the BDNF-induced phosphorylation of
Erk5, a known BDNF retrograde trafficking target. Mechanistically, the deficiency in trafficking was not due to
impaired endocytosis of the BDNF-TrkB complex, or impaired transport rate, since BDNF endosomes traveled
at the same rate in both control and IL-1β treatment groups. Among the regulators of presynaptic endosome sorting is
the post-translational modification, ubiquitination. In support of this possibility, the IL-1β-mediated suppression
of BDNF-induced Erk5 phosphorylation can be rescued by exogenous ubiquitin C-terminal hydrolase L1 (UCH-L1), a
deubiquitinating enzyme that regulates ubiquitin and endosomal trafficking.
Conclusions: We observed a state of neurotrophic resistance whereby, in the prolonged presence of IL-1β, BDNF is
not effective in delivering long-distance signaling via the retrograde transport of signaling endosomes. Since IL-1β
accumulation is an invariant feature across many neurodegenerative diseases, our study suggest that compromised
BDNF retrograde transport-dependent signaling may have important implications in neurodegenerative diseases.
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Background
Signaling by BDNF via the TrkB receptor is an important
mechanism supporting neuronal survival and activity-
dependent plasticity, which is critical for cognitive
function [1]. Receptor trafficking, including endocytosis,
sorting and transport, is key to BDNF signaling [2, 3].
BDNF follows many of the central tenets of the signaling
endosome hypothesis [4]. BDNF binds to its receptor,
TrkB, and signal transduction is mediated through the
receptor tyrosine kinase domain of the TrkB receptor. The
activated complex is propagated to both local and distal
subcellular compartments in endosomal vesicles. If the
signal initiates on the presynaptic terminal, the vesicle-
bound neurotrophins retrogradely traverse intracellular
compartments via dynein motors and are regulated by
Rab GTPases [5–7]. These endosomes therefore can carry
complete signaling complexes capable of activating
multiple intracellular cascades leading to plasticity and
survival. In cultured neurons, retrograde trafficking of
BDNF-signaling endosomes originating in presynaptic
compartments activates somal extracellular signal-regulated
kinase 5 (Erk5) [8].
Highlighting the significant role endosomal trafficking
dysfunction may play in neurological diseases comes
from the pathological enlargement of early endosomes
in the Alzheimer’s disease (AD) brain, and that many
AD-related genes identified as risk factors by genome-
wide association studies (GWAS) are involved in differ-
ent stages of endosomal trafficking (e.g., PICALM,
SORL1) [9, 10]. Moreover, disruption of ubiquitin
homeostasis, which regulates endosome sorting, is a
consistent observation in the pathophysiology associated
with Alzheimer’s disease (AD). Post-mortem analyses of
AD brains typically exhibit increased levels of ubiquitinated
proteins [11] accompanied by inhibition in proteosomal
degradation. Of particular interest is a deubiquitinating
enzyme, UCH-L1, which is part of a class of deubiquitining
enzymes that regulates bioavailability of ubiquitin and is
downregulated in AD. In APP/PS1 mice, injection of
UCH-L1 improves the retention of contextual learning
through the PKA-CREB pathway [12] and reduces Aβ
production, increased free ubiquitin and accelerates proteo-
somal degradation of APP [13]. In our past studies,
UCH-L1 rescued the BDNF-Erk5 retrograde trafficking
pathway caused by Aβ [14]. In this study, we aimed to
extend these findings to interleukin-1β (IL-1β).
IL-1β is a key component of the microglial-mediated
immune response in the brain and has deleterious
effects on cognition and synaptic plasticity at high or
chronic levels of exposure [15, 16]. In the mouse hippo-
campus, sustained expression of IL-1β impairs context-
ual and spatial memory [17]. We have reported that
IL-1β suppresses long-term potentiation (LTP), the
major cellular mechanism of learning and memory, and
BDNF-induced Akt, and CREB activation [18–21]; while
others have shown a link between acute neuroinflamma-
tion and disruption of specific neural circuit functions
and cognitive impairment [22]. Studies have also shown
that blocking IL-1β signaling can restore cognitive func-
tion [20, 23]. We hypothesize that the presence of IL-1β
undermines proper endosomal function and compro-
mises BDNF/TrkB signal transduction and synaptic
plasticity, placing the brain at risk for cognitive decline
and neurodegeneration.
Here, we introduce a new mechanism in which IL-1β
fundamentally alters BDNF-TrkB endosomal trafficking,
leading to measurable deficits in downstream target
Erk5. The nature of the trafficking aberration is not
related to vesicle transport rate, but is interrelated to
ubiquitin modification, since transduction of UCH-L1
rescues trafficking-dependent downstream effectors. We
suggest that in the presence of IL-1β, BDNF-TrkB endo-
some transport is impaired, leading to downstream
signaling deficits.
Methods
Primary neuronal cultures and treatments
The use of all animals was approved by the Institutional
Animal Care and Use Committee at the University of
California, Irvine. Primary neuronal cultures were
obtained from embryonic day 18 (E18) rat embryos.
Dissociated cells were cultured on either pre-coated
poly-L-Lysine 6-well plates (Biocoat plates, BD
Bioscience) or poly-L-Lysine coated glass coverslips
affixed to microfluidic chambers at 1 × 106 cells/9.5 cm2
and 5 × 106 cells/ml (for microfluidic chamber), respect-
ively. All cells were maintained in Neurobasal (Gibco)
supplemented with B27, penicillin/streptomycin, and
Glutamax at 37 oC, 5% CO2, 95% humidity. Rat recom-
binant IL-1β (PeproTech) was used at a final concentra-
tion of 10 ng/ml. Human BDNF (PeproTech) was used
at a concentration of 50 ng/ml and Ciliobrevin D
(Sigma) was dissolved in sterile Me2SO at 100 μM and
used at 1 μM.
Microfluidic chambers
The chambers were fabricated in PDMS using rapid
prototyping and soft lithography similar to previously
published procedures [24]. Glass coverslips (24 × 40 mm,
No. 1, Corning) sonicated in 95% EtOH (30 min) and
dried in a sterile hood were immersed in sterile aqueous
solution (0.5 mg/ml poly-L-lysine, Sigma) in PBS (24 h,
5% CO2, 37 °C incubator), rinsed, and allowed to air dry
in a sterile hood. The chambers are noncovalently
assembled and remained affixed to glass coverslips by
conformal contact. The chambers consist of two parallel
microfluidic compartments, connected by inlet and
outlet wells. The two compartments are separated by a
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solid barrier region with microgrooves embedded in the
bottom of the connecting barrier. A volume difference
between the two compartments of 20 μl is used to
generate a fluidic resistance within the microgrooves,
facilitating the isolation of treatments.
Live cell trafficking experiments
Endotoxin-free BDNF-GFP plasmid was introduced by
nucleofection (Lonza Amaxa) into HEK293 cells followed
by selection in DMEM containing 10% FBS and G418
(1 mg/ml, plasmid contains a neomycin cassette). BDNF-
GFP was isolated from stable pre-pro-BDNF-GFP
HEK293 lines after cells reached confluency. Secreted
BDNF-GFP from the media was removed and concen-
trated with Amicon YM-30 centrifugal filters (5000 × g,
2 h) (30,000 MW cutoff, Millipore). Pro-BDNF was con-
verted to mature BDNF-GFP by treatment with plasmin
enzyme (Sigma). Time-lapse microscopy on live cells was
utilized to measure the rates of BDNF-GFP-containing
endosomes within the microfluidic devices. Prior to treat-
ment, 20% of the cell culture media volume was removed
from the axon terminal (treated) side of the chambers.
BDNF-GFP or BDNF-GFP + IL-1β were then introduced
to the wells. Regions of interest from axon segments from
each chamber were randomly selected for time-lapse
imaging. After 1 h, transport rates were quantified on an
inverted Olympus IX70 with a 63× oil emersion objective.
The objective was focused on randomly chosen micro-
grooves of the chamber and imaged in a time-lapse in 5 s
intervals for 1 min. Image stacks from the time-lapse were
imported into ImageJ and tracked using ManualTracker.
These results were independently verified using Gradien-
Tech Particle Tracking Tool Software. For speed measure-
ments, we used the accumulated distance to time ratio.
For velocity measurements, we used the Euclidian
distance to time ratio.
Cell surface biotinylation assays
To assess TrkB internalization, primary neurons (7
DIV) were either treated with or without BDNF
(50 ng/ml) and then placed on ice to prevent further
TrkB internalization. The remaining cell surface TrkB
receptors were biotinylated with Sulfo-NHS-LC-Biotin
(100 mg/ml, 30 min; Thermo) and then washed with
0.1 M PBS (pH 7.5), three times. The cells were lysed
with radioimmunoprecipitation assay buffer containing
a protease inhibitor mixture (Roche Applied Science),
and biotinylated TrkB was precipitated with
streptavidin-agarose beads (Thermo, 50 μl) that had
been pre-equilibrated in radioimmunoprecipitation
assay buffer. To elute, precipitated proteins were
incubated in sample buffer and processed for Western
blot analysis.
Western blot analysis and antibodies
Following boiling or elution in Laemelli Sample Buffer
lysates were run on a complete Bio-Rad Western
Blotting System. Samples were electrophoretically sepa-
rated on Bio-Rad 10% Tris-TGX PreCast Gels and
blotted onto nitrocellulose membranes using Bio-Rad
Trans Turbo Dry transfer and buffer. All blots were
blocked using 5% BSA. The following is a list of all
primary antibodies used. Phosphorylated-Erk5 (T218/Y220)
(1:200, Cell Signaling), ERK5 (1:1000, Cell Signaling), TrkB
(1:1000, EMD Millipore). Immunoreactivity was measured
using Bio-Rad HRP conjugated secondaries. Blots were
developed on a Bio-Rad Digital Detection System running
ImageLab software, using Millipore Crescendo chemilu-
minescence development reagent. ImageJ was used for
band densitometry analysis. ImageJ quantification metrics
and western blots from the same lysate were ensured to be
reasonably reproducible, and all experiments were
reproduced using completely independent cultures from
different E18 litters.
Immunocytochemistry and antibodies
Cells were immediately placed on ice and washed gently
in ice-cold HBSS. Cells were then fixed in fresh, ice-cold
4% paraformaldehyde for 20 min. The microfluidic
chamber devices were removed from the coverslip and
cells were fixed again in 4% paraformaldehyde (20 min).
Cells were blocked (cold 5% BSA in 0.1 M PBS) and
permeablized (0.02% Triton-X100 in 0.1 M PBS)
followed by primary antibody, overnight. The following
antibodies were used in this study (Anti-GFP 488 conju-
gate, Life Tech, 1:200; anti-synaptophysin, Millipore,
1:200; Tau-1 (1:200), followed by Alexa conjugated goat-
anti-X secondary antibody (Life Tech, 1:200, X = primary
host). All images were collected using a Leica confocal
microscope. Regions of interest [9] were randomly
chosen and imaging proceeded serially and sequentially.
ImageJ was used to define the number of terminals as
the number of defined puncta positive for the synapto-
physin marker and to define colocalization consistently
across all sections. The output measure was linear dens-
ity (events per μm) of colocalized events. Axon segments
totaling 2445 total terminals were analyzed. For UCHL1
experiments, cell culture medium (40 μl) was removed
from each axonal well prior to the addition of BDNF
(50 ng/ml) to restrict BDNF to only the axonal compart-
ment. After 90 min treatment, somal compartments
were analyzed for phos-Erk5 activation by immunocyto-
chemical analysis as described previously [14]. In brief,
the microfluidic devices were removed, and the cover-
slips were rinsed with PBS, paraformaldehyde-fixed (4%),
permeabilized in 0.25% Triton X-100 in PBS (pH 7.4),
and blocked with 5% goat serum. The cells were incu-
bated in appropriate primary antibody overnight at 4 °C.
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phos-Erk5 was stained with anti-phos-Erk5 (1:1000; Cell
Signaling) followed by anti-mouse Alexa 488. The cells
were washed and then immunolabeled with TO-PRO3
(Invitrogen) to identify nuclei. Images were captured by
Zeiss LSM510 two-photon microscope. The mean pixel
intensity for each cell was determined and normalized to
TO-PRO3.
Flow cytometry analysis
All the steps for synaptosome P2 fraction isolation were
carried out at 4 °C; sucrose buffer, grinder, pestle, and
microfuge tubes were all pre-cooled on ice. Rat neuronal
cultures >12DIV were gently homogenized in 0.32 M
sucrose containing HEPES [10 mM] and protease/phos-
phatase inhibitors cocktail (Pierce), pH 7.4. The extracts
from individual wells, containing 1 × 106 neurons, were
pooled. Homogenization consisted of 6–8 manual
strokes in a glass-Teflon grinder, clearance (between
plunger and glass): 0.15–0.25 mm. Plunger was gently
rotated during strokes while the grinder was kept on ice.
The extract was first centrifuged at 1000 × g for 10 min;
the resulting supernatant was centrifuged at 13,000 × g
for 20 min to obtain the crude P2 pellet, which was re-
suspended in ice-cold PBS. A P2 fraction aliquot was
used to determine protein concentration (BCA assay
using BSA as a standard). Synaptosomal P2 fractions
were subjected to established immunolabeling protocols
to intracellular detection by flow cytometry, as previ-
ously described [7, 20, 25], reproduced here, in brief. P2
fractions were fixed in 2% paraformaldehyde and perme-
abilized in 90% methanol. After labeling, pellets were
washed twice and then resuspended in PBS buffer
(0.5 ml) for flow cytometry analysis. Anti-Synapsin-1
IgG was labeled directly with Alexa Fluor 647 (Cell
Signaling). Background fluorescence thresholds were set
by immunolabeling with host-IgG-647 isotype matched
control on a non-GFP-treated sample. Comparisons
were made from 3 independent pooled samples. Percent
gated events positive for both synapsin-1 and GFP were
used for the analysis. Samples were acquired using a
Becton Dickinson FACSCalibur flow cytometer (BD
Biosciences, San Jose, CA, USA) equipped with argon
488 nm and helium-neon 635 nm lasers. Relative size
and granularity was determined by forward (FSC) and
side scatter (SSC) properties. FSC, SSC, and fluorescence
(FL1 [530 ± 15 nm] and FL4 [650 ± 25 nm]) signals were
collected using log amplification. FSC-SSC plots were
used to select particles matching the size of synaptosomes
(0.75–3.0 μm) using calibrated beads (Polysciences, Inc.)
as previously described [20, 25]. Identical FSC settings
were used for acquiring data on bead standards and
samples. Small fragments and debris were excluded by
establishing a FSC-H threshold (gain =325). Ten thousand
size-gated particles were collected and analyzed for each
sample; event rate: approximately 500/s. Analysis was
performed using the FlowJo v10 software (FlowJo LLC).
Results
IL-1β has been previously shown to impair BDNF signal-
ing pathways [18–21]. It is possible that endosomal
trafficking of BDNF and signaling pathways activated by
BDNF are not independent of each other. The central
aim of this study is to define and to begin characterizing
the mechanism by which IL-1β affects the trafficking of
the BDNF endosomal signaling complex itself. Here, we
put forth the evidence as to nature and extent to which
IL-1β affects BDNF endosome trafficking. We measured
the extent to which BDNF-GFP was found colocalized
to presynaptic compartments and found that IL-1β treat-
ment was associated with a 2.6-fold increase in BDNF-
GFP colocalization (Fig. 1a–e, p < 0.05, Fisher’s exact
test), suggesting there was a significant correlation in a
controlled experimental culture between IL-1β treat-
ment and localization of these vesicles. To confirm and
extend these observations and measure presynaptic
BDNF-endosome clustering by alternative method, we
isolated P2 synaptosomal fractions (enriched in synapto-
somes [26]) from neuron cultures, as previously
described [27, 28]. We and others have previously shown
that synaptosomes can be identified by flow cytometry
using size-calibrated beads [25, 29–31], a strategy based
on the analysis of the forward-scattered (FSC) light
which is proportional to the size of particles (Fig. 1f ).
Using our synaptosome immunostaining protocol [31],
we examined the population of size-gated synaptosomes
that were positive for presynaptic marker synapsin-1 and
GFP, as an indication of BDNF-endosome clustering at
the presynaptic terminal at the time of collection. By this
approach, we found that size-gated synaptosomes
positive for both synapsin-1 and BDNF-GFP were in-
creased in cells exposed to IL-1β (Fig. 1g), suggesting
increased colocalization of BDNF-GFP at presynaptic
terminals by two independent experimental methods.
Next, we assessed long-range retrograde trafficking
using microfluidic chambers we developed that allow the
fluidic separation of axons and presynaptic boutons from
cell bodies by a distance of 450 μ. This cell culture
platform directs the growth of axons from one compart-
ment through a barrier region into an adjacent fluidi-
cially separated target compartment. Thus, any BDNF-
GFP introduced to the presynaptic terminal side can
only arrive in the somal compartment via long-range
intra-axonal retrograde trafficking mechanisms (Fig. 2a–c).
We selectively introduced BDNF-GFP or BDNF-GFP+ IL-1β
to the presynaptic compartment and quantified BDNF-GFP
endosomes in the somal compartment 1 h thereafter
as a measure of retrograde trafficking. We found
that IL-1β treatment reduced BDNF-GFP endosome
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counts by 29 ± 10% relative to BDNF-GFP-only treat-
ment controls (100 ± 6%, n = 9, p < 0.05) somal com-
partments (Fig. 2d–h), suggesting long-range BDNF
endosome flux is attenuated by IL-1β.
If trafficking deficits are truly associated with IL-1β,
then we would expect a long-range BDNF endosome
target to also be impaired by IL-1β. Erk5 is a well-
established target kinase of BDNF-TrkB endosomes and
a central signaling component of gene transcription
related to neuronal survival [8, 32]. Evidence has shown
that Erk5 becomes phosphorylated in the presence of
BDNF and typically demonstrates somal localization and
nuclear translocation upon neurotrophin-induced phos-
phorylation. Erk5 is the first MAP kinase identified
whose activity is stimulated by neurotrophins but not by
neuronal activity [32]. We therefore tested whether
IL-1β could cause downstream signaling deficits to
BDNF endosome-induced phosphorylation of Erk5. In
cultured neurons, our results indicate that BDNF treat-
ment (50 ng/ml) increases phosphorylated Erk5 (phos-
Erk5) 2.1 times baseline (±16%, n = 4 independent
cultures), while the BDNF + IL-1β group only increased
phos-Erk5 levels to 1.2 times baseline (±23%, n = 3 inde-
pendent cultures, p < 0.05) (Fig. 3a). To mitigate other
possible confounding factors such as BDNF dependent
activation of Erk5 via non-trafficking pathways (e.g.,
somal TrkB, signaling cascades), we inhibited the
retrograde trafficking pathway using Ciliobrevin D, a
cell-permeable benzoyl dihydroquinazolinone deriva-
tive that acts as a reversible and specific blocker of
AAA+ ATPase motor cytoplasmic dynein. The remaining
BDNF-induced phos-Erk5 would indicate the contribution
of non-trafficking dependent phos-ERK5 activation.
Figure 3b shows the western blot analysis of phos-Erk5
levels in response to BDNF and BDNF + Ciliobrevin D
treatment groups. BDNF-dependent phos-Erk5 increased
Fig. 1 Increased presynaptic colocalization of BDNF-GFP caused by IL-1β as an indicator of reduced endosome transport. Presynaptic colocalization of
BDNF-GFP was examined by immunostaining of BDNF-GFP and synaptophysin. Neurons were fixed and analyzed after 1 h post-treatment to assess
BDNF-GFP endosome dispersion through neurites (illustrated by traces) in culture. a–d Representative images that show neurons treated
with BDNF-GFP (a and c) or BDNF-GFP + IL-1β (b and d) and stained with antibodies against GFP [34], synaptophysin [52], and tau-1 (blue). Scalebars:
10 μm in a–b and 2 μm in c–d. e Quantification of the colocalization of BDNF-GFP and synaptophysin in neurons treated with BDNF-GFP or BDNF-GFP +
IL-1β. IL-1β treatment was associated with a 2.6-fold increase in BDNF-GFP/synaptophysin colocalization. Graph depicts mean± SE (as fold relative to BDNF);
BDNF= 2.6 ± 0.4, n= 3 vs BDNF + IL-1β= 1.0 ± 0.2, n= 3 independent cultures. f P2 fractions were isolated from three independent cultures and pooled as
an alternate means of colocalization. By flow cytometry analysis, forward-Side (FSC-SSC) density plot shows the size-complexity profile of particles in the P2
fraction isolated from hippocampal cultures. The gate (inside rectangle) selects according to size (0.75 < gated particles < 3.0 μm), relative to calibrated beads
(f, lower panel) [34, 52]. g The population of size-gated synaptosomes was probed for the presence of the presynaptic marker synapsin-1 and BDNF-GFP.
The presence of GFP signal in synapsin-1-positive events was used as an indicator BDNF-GFP retained in presynaptic compartments.
BDNF + IL-1β groups exhibited a fourfold increase in GFP events colocalized with synapsin-1 (n = 3 independent cultures pooled).
Thresholds for endogenous/non-specific fluorescence for each marker were set using untreated (no BDNF-GFP) synaptosomal fractions stained with an IgG
isotype-matched conjugated to Alexa 647
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to 1.8 times baseline (±14%), while Ciliobrevin D at-
tenuated the level of BDNF-induced phos-Erk5, reach-
ing only 1.08 times baseline (±25%, n = 5 independent
cultures, p < 0.05). Since the IL-1β-induced inhibition
of trafficking resulted in near baseline levels of phos-
Erk5 even in the presence of BDNF, we conclude that
there is a functional and measureable consequence of
our observations in Figs. 1 and 2. To further extend
Fig. 2 IL-1β reduces trans-axonal long-range BDNF endosome volume flow. a Top-down schematic of neurons in microfluidic chambers. b Edge
on schematic (upper panel) and top-down microscope image (lower panel) of the three compartments in the microfluidic chambers. c Representative
neuron culture in microfluidic chambers. d and e Presynaptic boutons in axon terminal compartment were treated with BDNF-GFP or
BDNF-GFP + IL-1β, after which GFP-fluorescence data was collected by analyzing linear density along axons treated in microfluidic chambers. Fluorescence
by BDNF-GFP endosomal in the somal compartment was analyzed for as an indicator of BDNF-GFP that arrived via long-range trans-axonal transport
mechanisms. Every attempt was made to exclude dendrites from the analysis (e.g., only quantifying along tau-positive segments and only treating the
axonal side), thus, everything in the somal side must have arrived via axonal transport. Images are of somal compartments. f and g Neurites showing a train
of BDNF-GFP endosomes in 3D (upper) and 2D (lower). Three-dimensional images represent intensity peaks and were used for quantification. h Quantification
of axon-associated BDNF-GFP in soma compartment. BDNF+ IL-1β treatment resulted in a 34 ± 9% decline in GFP linear density (unpaired t test, p< 0.05),
relative to BDNF. Mean± SE; BDNF= 1.0 ± 0.08, n= 9 vs BDNF+ IL-1β= 0.72 ± 0.08, n=6, unpaired two-tailed t test, p< 0.05)
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these findings to a more complex model system, we
confirmed that the connection between IL-1β and
BDNF-induced phos-Erk5 can also be observed in an
acute brain slice assay from 3-month-old rats.
Coronal slices prepared from sacrificed rats were treated
with recombinant BDNF in the left hemispheres and were
compared to BDNF + IL-1β treatments in the animal’s
corresponding right hemisphere. By this design, we were
able to test both groups, BDNF and BDNF + IL-1β within
the same animal. Consistent with the data from our
neuron culture experiments, we found that IL-1β reduced
BDNF-induced phos-Erk5 14% (n = 4, t test paired, two
tailed, p < 0.05) (Fig. 3c).
In previous studies, we found that soluble Aβ oligo-
mers (principle neuropathological aggregate of AD) also
attenuated BDNF trafficking by reducing the actual rate
of transport of BDNF endosomes on axonal microtu-
bules. Since our observations with IL-1β were similar,
we asked if there was a common mechanism and if
IL-1β affects the rate of transport. We quantified the
velocity and speed in live-cell retrograde trafficking
experiments to determine if IL-1β-induced endosomal
trafficking deficits are directly caused by reduced endo-
some transport rate. BDNF-GFP particles exhibited a
mean rate of 0.35 μm/s (n = 10), compared to BDNF-
GFP endosomes in cells treated with IL-1β, which exhib-
ited a slightly faster but not significantly different mean
rate of 0.5 μm/s (n = 8). From these data, we conclude
that IL-1β does not reduce BDNF-GFP endosomal
trafficking rates (Fig. 4a). To further analyze the charac-
ter of BDNF endosomal motility, velocity/speed ratios
were used as a metric to elucidate the extent to which
the endosomal velocity vector was concentrated in
actual retrograde motion, as opposed to other observed
phenomenon such as stalling, fluttering, or spontaneous
reversal (anterograde motion). Since this metric would
be sensitive to other motile characteristics, it gives a
generalized indication of motile character. Again, we
found that the velocity/speed ratios of vesicles in both
groups exhibited very similar mean values around 90%
retrograde directedness for both groups (Fig. 4b,
BDNF: mean ± SEM = 93 ± 3%, n = 10, BDNF + IL-1:
mean ± SEM = 87 ± 5%), collectively suggesting that
neither rates nor transport characteristics are appre-
ciably altered by IL-1β in our cultures.
We next tested whether BDNF-TrkB endocytosis itself
was impaired. If less BDNF-GFP endosomes were inter-
nalized, it could account for, in part, reduced long-
distance BDNF-GFP counts observed in Fig. 2. We used
a cell surface biotinylation assay (EZ-Link LC-Biotin,
Thermo) to measure whether BDNF-induced TrkB
internalization was at all affected by IL-1β over the rele-
vant timecourse of IL-1β treatment. We could find no
evidence that IL-1β impaired endocytosis of BDNF
Fig. 3 IL-1β attenuates BDNF-induced phosphorylation of retrograde signaling target Erk5. a Levels of phos-Erk5 were measured in cultured neurons
with BDNF or BDNF + IL-1β treatments. Neurons treated with BDNF exhibited twofold increase in phos-Erk5 levels over baseline non-treated controls
while BDNF+ IL-1β treatment exhibited only a 1.3-fold increase in phos-Erk5 levels over baseline, suggesting IL-1β attenuates BDNF-induced phosphorylation
of Erk5. Mean ± SE; BDNF = 2.0 ± 0.2, n = 4 independent cultures vs BDNF + IL-1β = 1.1 ± 0.2, n = 3 independent cultures, unpaired two-tailed
t test, p < 0.05). b Levels of phos-Erk5 in response to BDNF in the presence of Ciliobrevin D (BDNF + CiB-D)B were reduced to baseline: mean ± SE;
BDNF = 1.9 ± 1.4-fold, n = 5 independent cultures vs BDNF + CiB-D = 1.1 ± 0.25-fold (by unpaired t test p < 0.05) c Levels of phos-Erk5 in ex vivo slices
with BDNF (left hemisphere) or BDNF + IL-1β (right hemisphere) compared in adult rats that exhibited 14 ± 2% decrease in phos-Erk5 levels after treatment
with BDNF + IL-1β when compared to BDNF-only treatment. Graph rescaled such that xBDNF=1.0. Mean ± SE; BDNF = 1.0 ± .02-fold, n = 4
animals vs BDNF + IL-1β = 0.84 ± .02-fold, n = 4 animals, paired t test: p < 0.05)
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(mean ± SE =72 ± 9%, n = 2 independent experiments vs
BDNF + IL-1β: mean ± SE = 0.70 ± 10%, n = 2 independ-
ent experiments). In fact, to our surprise, IL-1β may be
associated with a slight increase in endocytosis at earlier
timepoints (Fig. 5). In the presence of Dynasore
(80 μM), an inhibitor of dynamin [33], BDNF-induced
TrkB internalization was suppressed (Fig. 5b), support-
ing the view that IL-1β does not affect BDNF-induced
internalization of TrkB. In the absence of altered
trafficking kinematics and endocytosis, it follows IL-1β
may regulate the egress, or the process of transitioning
from presynaptic trafficking mechanisms to long-range
axoplasmic trafficking mechanisms. Among regulators of
presynaptic endosome, sorting is the post-translational
modification, ubiquitination.
Because ubiquitin is a widely pervasive mechanism
governing synaptic sorting of endosomal cargo, we
investigated the effect by introducing a transducible
TAT-UCH-L1. UCH-L1 has been shown to restore
normal enzymatic activity and synaptic function both in
hippocampal slices treated with oligomeric Aβ and in
the APP/PS1 mouse model of AD. Based on our previ-
ous findings that UCH-L1 rescues BDNF/TrkB retro-
grade transport deficits induced by Aβ [14], we believe
Fig. 5 IL-1β does not measurably alter cell surface TrkB expression. a Cell
surface TrkB was measured in a 1-hour timecourse in response to BDNF
or BDNF + IL-1β. Following treatment, endocytosis was arrested and cells
were biotinlyated (see Methods). Cell surface TrkB levels did not
differ significantly among groups over 1 h. The average rate of
endocytosis per 1 h was 53% for TrkB150 after treatment with BDNF vs
47% following treatment with BDNF + IL-1β, suggesting that IL-1β does
not significantly alter endocytic kinetics of TrkB at 1 h. Rates
ΔCS-TrkB95/hr: BDNF = –72 ± 9%, n = 2 independent experiments
vs BDNF + IL-1β = –0.70 ± 10%, n = 2 independent experiments).
Rates ΔCS-TrkB150/hr: BDNF = –72 ± 9%, n= 2 independent experiments
vs BDNF + IL-1β= –0.70 ± 10%, n= 2 independent experiments). b Cell
surface TrkB-full length (TrkB-FL) was measured in a 1-h timecourse in
response to BDNF, BDNF + IL-1β, or BDNF +Dynasore, an inhibitor of
dynamin. Dynasore, but not IL-1β, suppressed BDNF-induced TrkB
internalization. Upper panel: the image of western blotting. Lower upper
panel: quantification of western blotting data (mean ± SE, n = 2)
Fig. 4 Signaling deficits not associated with a decline in the rate of
transport. a Displacement vs time of retrograde vesicles in BDNF or
BDNF + IL-1β conditions. Endosomes traveled at an average of
0.35 (n = 10 cultures used to acquire the data) and 0.5 (n = 8) μm/s.
Therefore, IL-1β does not reduce the rate of transport of BDNF-GFP
vesicles. Graph is mean ± range of all values. Transport data were
collected from axons running through a single microfluidic groove
(<10). b Ratio of endosomal velocity to speed, indicating directedness
of motion. There is a very minimal difference between the means.
Mean ± SE; BDNF = 0.93 ± 0.3, n = 10 vs BDNF + IL-1β = 0.87 ± 0.5, n = 8.
IL-1β does not alter the character of vesicle locomotion. n refers to the
number of cultures used to acquire the data. c 3D kymographs of BDNF
and d BDNF + IL-1β treatment groups. The 3D kymograph
shows the position/time motion of a single vesicle from each
group (X-axis = position, Y-axis = time, Z-axis = intensity)
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UCH-L1 is a mechanistically interesting and relevant
protein of interest. The effect of UCH-L1 on IL-1β-
induced impairment of BDNF was examined by measur-
ing BDNF-induced phosphorylation of Erk5 in somal
compartment in microfluidic chambers. Like IL-1β and
BDNF, TAT-UCH-L1 was applied distally to axon termi-
nals in a distinct fluidic environment from cell somas,
which resided in a somal compartment that was 450 μm
across a fluid barrier. As shown in Fig. 6, BDNF treat-
ment in the axonal compartment increases phosphoryl-
ation of phos-Erk5 in somal compartment 2.4 times
baseline ± 26%, n = 3 independent cultures), while the
BDNF + IL-1β group only increased phos-Erk5 levels to
1.2 times baseline (±12%, n = 3 independent cultures).
Importantly, UCH-L1 treatment rescued IL-1β-induced
impairment of BDNF retrograde signaling to 1.8 times
baseline ± 23%, n = 3 independent cultures). Our data
indicate that IL-1β interferes with pathways that are
associated with ubiquitin homeostasis or can at least be,
in part, regulated by ubiquitin.
Discussion
In the current study, we demonstrate that IL-1β impairs
BDNF retrograde trafficking. We show that neurons
cultured in microfluidic chambers, which fluidically
isolate presynaptic terminals from cell bodies, exhibit
sustained long-range retrograde transport deficits in the
presence of IL-1β. The cytokine-induced long-range traf-
ficking deficit was also evidenced by the inhibition of
phos-Erk5, the BDNF endosome retrograde trafficking
target. The trafficking defect within the presynaptic
compartment was confirmed by synaptosome isolation
from cultured hippocampal neurons after IL-1β treat-
ment and immunostaining for BDNF-GFP. IL-1β treat-
ment increased the size-gated events positive for both
synaptophysin and BDNF-GFP, confirming increased
colocalization of BDNF-GFP at presynaptic terminals.
The BDNF-induced Erk5 activation, which is impaired by
Aβ in our previous study [14] and by IL-1β in our current
study, has important functional implications for neuronal
survival, neurogenesis, and hippocampal-dependent learn-
ing and memory. Erk5 mediates neurotrophin-induced
changes in gene expression necessary for neuronal survival,
notably upregulation of bcl-w, an anti-apoptotic bcl-2
family member [32, 34]. In addition, Erk5 can be activated
by neurotrophins in adult neural stem/progenitor cells,
promoting neurogenesis in the adult brain [35, 36]. Notably,
genetic activation of ERK5 increases adult neurogenesis in
the dentate gyrus and improves spatial learning and long-
term memory persistence [37]. Taken together, the litera-
ture and our data suggest that IL-1β-induced impairment
of BDNF-dependent Erk5 action may contribute to the
deleterious role of inflammation in aging and neurodegen-
erative diseases. Previously, we reported that Aβ applied to
Fig. 6 UCH-L1 rescued the IL-1β effect on BDNF-induced Erk5 phosphorylation. phos-Erk5 activation was measured in somal compartment. a Low
magnification images of neurons immunolabeled with antibody against phos-Erk5 or imaged with phase-contrast filter (middle). The images show
somal and axonal compartments, which were separated by microgrooves (between the dash lines). Scalebar, 100 μm. b The representative images that
demonstrate that BDNF led to an increase in somal phos-Erk5. IL-1β decreased BDNF-induced elevation of somal phos-Erk5 levels. In the presence of
UCH-L1, the inhibitory effect of IL-1β was reduced. phos-Erk5 immunoreactivity was normalized to the nuclear counterstain, TO-PRO 3. c Quantification
of somal phos-Erk5 levels. BDNF treatment significantly increased somal phos-Erk5 levels (*, p < 0.05, n = 3). In the presence of IL-1β, BDNF treatment
did not lead to an elevation of somal phos-Erk5 levels. In the presence of UCH-L1 and IL-1β, BDNF treatment increased somal phos-Erk5
levels (*, p < 0.05, n = 3). Scalebar, 20 μm. Veh, vehicle
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axons in microfluidic chambers impaired retrograde flow
and resulted in long-range BDNF transport deficits, leading
to suppression of downstream Erk5 activity [14]. Consistent
with our previous study on Aβ [14], IL-1β decreased
BDNF-retrograde transport-dependent Erk5 activity in
hippocampal neuronal cultures and reduced BDNF-
dependent phosphorylation of Erk5 in adult brain slices. It
is noteworthy that the inhibition of Erk5 activation was
found to be more evident in pure neuronal cultures than in
slices, thus, suggesting that the mechanism underlying
BDNF-ERK5-IL-1β interactions is, basically, neuron-
specific. Indeed, we have recently described that IL-1β
suppresses activity-dependent signaling directly at the syn-
apse [25]. Importantly, Aβ was associated with a reduced
rate of BDNF endosomal transport, IL-1β did not affect the
rate of BDNF/TrkB endosome transport, suggesting that
Aβ and IL-1β act via distinct mechanisms and may be able
to act synergistically to impair the retrograde trafficking
pathway. A tempting but simplified model for AD may rely
on a reduced rate of endosomal transport in neurons by
early accumulation of Aβ, which also promotes a rise in
brain IL-1β levels [38]. According to our data, Aβ and IL-
1β may synergistically impair the retrograde trafficking
pathway (via different mechanisms), thus, contributing to
cognitive impairment in late AD stages.
Our data, that IL-1β has no significant effect on TrkB/
BDNF endocytosis or actual transport rates of BDNF/TrkB
endosomes, suggest that the deficit in BDNF retrograde
trafficking likely stems from impaired endosomal trafficking
from the presynaptic terminals and endosome loading onto
the retrograde transport system. Potential contributing
mechanisms underlying the deficit may include alterations
to trafficking accessory protein complexes (such as Rab/Rac
family), changes at the level of retromer complexes, actin
dynamics, or altered regulation of ubiquitination. Any of
these mechanisms would lead to accumulation of BDNF
endosomes in presynaptic terminals. Importantly, ubiquiti-
nation has been shown to play a critical role in delivery of
receptors to multivesicular endosomes (MVBs), the major
sorting platform for membrane proteins including trophic
factor receptors [39, 40]. Thus, altered regulation of ubiqui-
tination may contribute to IL-1β-induced deficit in endo-
some loading. It is also possible that regulation of
ubiquitination affects other molecules that play key role in
BDNF retrograde transport including dynein [41, 42] and
Pincher [43]. It remains for future research to explicitly
identify the molecular mechanisms underlying IL-1β-
induced impairment in BDNF retrograde trafficking.
Disruption of actin dynamics may be a particularly
relevant mechanism, given that actin dynamics have
been shown to play a key role in the regulation of early
endosome dynamics. For example, in Caenorhabditis
elegans, disruption of the Arp2/3 complex (which regu-
lates branched actin dynamics) led to significantly larger
early endosomes but did not affect endocytosis [44]. In
addition, our previous studies have demonstrated that
IL-1β impairs BDNF signaling [18, 20, 21] by targeting
actin polymerization [18], and that IL-1β impairs BDNF
dependent LTP by preventing F-actin formation and
spine stabilization [18].
We previously demonstrated that impaired retrograde
transport in the presence of Aβ occurs through an
ubiquitin-dependent mechanism, and that the deubiquit-
ing enzyme UCHL-1 restores retrograde transport of
BDNF/TrkB [14]. Here, we investigated if there is a simi-
lar role for ubiquitination in the retrograde transport
deficit induced by IL-1β, by introducing a transducible
TAT-UCHL-1 construct. We found that UCHL-1
restored BDNF/TrkB transport not only in the presence of
Aβ but also with IL-1β, suggesting the two agents share a
common mechanism of interfering with ubiquitination-
dependent trafficking mechanisms. In support of our data,
previous studies demonstrated that ubiquitination regu-
lates Trk receptors endocytic trafficking to multivesicular
bodies for sustained retrograde signaling [40, 43, 45].
Thus, the IL-1β induced impairment of ubiquitin homeo-
stasis may exacerbate the suppressive effect of Aβ on
endosomal trafficking and synaptic impairments.
Our results support previous studies that have
reported disrupted vesicle transport in AD, one of the
earliest pathological features in the AD brain and in ani-
mal and cell-based models of AD [46, 47]. These studies
have shown early endocytic changes including an
increased volume of early endosomes as an early stage of
several neurological diseases, including AD and Down
syndrome [48, 49]. In addition, in amyotrophic lateral
sclerosis, endosomes accumulate APP in motor neurons
reflecting impaired vesicle trafficking [50], while in Par-
kinson’s disease, α-synuclein multimers cause synaptic
vesicles to cluster and traffick to be attenuated [51].
Taken in context with our findings, neuropathology
and chronically upregulated IL-1β may act additively
or even synergistically to incapacitate the steady-state
vesicle flow throughout the cell and impair neuronal
function in various neurodegenerative diseases.
Conclusion
Our findings extend previous data on the role of IL-1β
in neuronal function and show that IL-1β can impair
endosomal trafficking and contribute to synaptic and
neuronal dysfunction. Endosomal dysfunction can be
interrelated to a number of signaling deficits. Because
ligand-activated signaling cascades depend on ligand-
receptor activation, and activated receptors are distrib-
uted intracellularly via endosome transport, it follows
that proper endosomal transport is a vital component of
many signaling cascades. Endosomal transport dysfunction
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is a cell-wide problem, since virtually all classes of cell-
surface receptors that undergo endocytosis, recycling, or
sorting depend heavily on proper endosome trafficking. It
is likely that IL-1β impairs endosomal trafficking for other
neurotrophic factors besides BDNF, a topic that warrants
further investigation.
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